Roche Holding named the architect of its integration plan with Genentech to head the Swiss group's dominant drugs business, putting the finishing touches to this spring's $47 billion (Dh172.63bn) buyout of the US biotech firm.

Roche said yesterday that industry insider Pascal Soriot would replace veteran William Burns as head of its pharma division at the end of the year – the final move in a management reshuffle started when Severin Schwan took over as Chief Executive last year.

"The appointment of internal members that have a solid track record within Genentech and Roche is expected to bring continuity in Roche's business," said Kepler Capital Markets analyst Daniel Daetwyler.

"In particular, the fact that the current CEO of Genentech has been appointed to COO Pharma gives a clear signal of the integration of Genentech in the whole Roche organisation."

Soriot was appointed CEO of Genentech in April and has been leading the integration of the business with Arthur Levinson, the previous head of the US biotech group. Roche also named Daniel O'Day, who currently heads its molecular diagnostics business, as new chief of the diagnostics division and announced a series of other appointments.

The drugs unit accounted for some 80 per cent of Roche's 2008 sales of SF46bn (Dh161.61bn) and diagnostics made up the remainder.

Roche has used its buyout of Genentech, in which it previously held a majority stake, to shake up its operations in the United States and increase its focus on biotech drugs as pharmaceuticals makers struggle to develop conventional medicines.

Roche now describes itself as a biotechnology company.

Its US operations are to operate under the Genentech name, with its research, development and commercial operations all based at the US group's San Francisco headquarters.

 

Keep up with the latest business news from the region with the Emirates Business 24|7 daily newsletter. To subscribe to the newsletter, please click here.